Stock Ratings / Consumer Discretionary / AHG / forecast

RSKD (55) QNST (70) LQDT (74) NUTX (86) ⌘ Pro Terminal →

Akso Health Group ADS (AHG) 12-Month Stock Forecast & Price Target Cone

$1.26 -5.26% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.25

Akso Health Group ADS (AHG) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $1.14B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AHG Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AHG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Akso Health Group ADS (NASDAQ: AHG) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.26 (-5.26% 1D, market cap $1.14B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1011 tracked Consumer Discretionary issuers, AHG ranks #823 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AHG compare to RSKD and QNST in the Consumer Discretionary sector?

▼

Within the Consumer Discretionary sector (Business Services), AHG carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of -0.1%, and ROIC of —. By comparison, RSKD (Riskified Ltd. (Class A)) holds a D+ grade (55/100 RQD, P/E N/A, ROIC -20.3%, cap $1.22B) and QNST (QuinStreet Inc.) posts a B- grade (70/100 RQD, P/E N/A, ROIC 2.6%, cap $980.8M). Among the 5-stock peer group, NUTX leads on earnings multiple (20.3x) while NUTX leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AHG?

▼

Per AHG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001702318), Akso Health Group ADS generated $13.8M in revenue (-6.4% YoY), -$18.7M in net income, and -$12.8M in free cash flow against $212.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Discretionary with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.25 (-1.14%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-11.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AHG)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY AHG SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (29% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.37-2.9% Next Q

Q2 (-2Q)

Grade E$1.33-4.5% Next Q

Q3 (-1Q)

Grade E$1.27-0.8% Next Q

Current

Grade E$1.26-8.7% Hist 90D α

Trajectory: D (42) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AHG Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AHG currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Consumer Discretionary with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.03) and Max Pain ($1.32) forces dealer call-delta covering toward $2.63.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AHG• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AHG Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your AHG Position Size: $10,000

Shares at $1.26: 7936.5 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $0.87

$6,905

$-3,095 (-31.0%)

12M Consensus BaseTarget $1.12

$8,889

$-1,111 (-11.1%)

12M Bull Case BreakoutTarget $2.63

$20,873

+$10,873 (+108.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$1	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$2	69%	B
JP MorganUS Large-Cap Research	SELL	$1	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AHG)

✓Walkthrough of AHG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AHG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -41.12%▼ DESCENDING CHANNEL

2026-11-02O $1.30H $1.33L $1.26C $1.26VOL 33.1K

RES: $1.49SUP: $0.50SMA50: $1.03SMA200: $1.51

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AHG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AHG Butterfly Map → + Track AHG →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -6.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AHG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AHG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AHG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AHG)

Consumer Discretionary Rank #823 of 1011 ⚔️ RSKD vs AHG Full Matrix →

1. Head-to-Head Consumer Discretionary Peer Comparison (AHG vs. RSKD, QNST, LQDT, NUTX)

Industry: Business Services (90 Tracked Issuers)

Across 1011 tracked Consumer Discretionary securities in the Roarable RQD universe, Akso Health Group ADS (AHG) ranks #823 by composite RQD confidence (34/100, grade E) and #499 by equity capitalization ($1.14B). Within this direct 5-issuer industry benchmark cohort, NUTX leads on earnings valuation at 20.3x trailing P/E, while NUTX leads on capital efficiency and profitability with 85.0% ROIC and 50.8% gross margin. NUTX currently holds the highest overall quantitative score in the immediate peer group at 86/100 (A) compared with AHG at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AHG ACTIVE Akso Health Group ADS	E	34/100	—	-0.1%	—	-5.26%	$1.14B	Benchmark Subject
RSKD Riskified Ltd. (Class A)	D+	55/100	—	51.7%	-20.3%	-4.67%	$1.22B	/rskd-vs-ahg →
QNST QuinStreet Inc.	B-	70/100	—	10.1%	2.6%	+1.52%	$980.8M	/qnst-vs-ahg →
LQDT Liquidity Services Inc.	B	74/100	50.5x	43.8%	12.9%	-1.48%	$1.42B	/lqdt-vs-ahg →
NUTX Nutex Health Inc.	A	86/100	20.3x	50.8%	85.0%	-4.74%	$1.44B	/nutx-vs-ahg →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001702318

In its most recent audited fiscal period (FY2025, filed 2026-03-31), Akso Health Group ADS (AHG) reported GAAP revenue of $13.8M (-6.4% vs. FY2024 revenue of $14.8M , and +472.9% cumulative change since FY2023) , GAAP net income of -$18.7M, operating cash flow of -$12.8M, and free cash flow of -$12.8M (-1350.9% YoY). On the balance sheet, AHG closed FY2025 with $212.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-03-31	$13.8M	-$18.7M	-$12.8M	-$12.8M	$212.0M	—
FY2024 (FY)	2025-03-31	$14.8M	-$135.0M	$1.2M	$1.0M	—	—
FY2023 (FY)	2024-03-31	$2.4M	-$9.5M	$1.4M	$1.4M	—	—

3. AHG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AHG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does AHG compare to RSKD and QNST in the Consumer Discretionary sector?

What are the biggest fundamental strengths and SEC risk factors for AHG?

Where is AHG trading relative to its 50-day, 200-day, and 52-week technical levels?

AHG last traded at $1.26 (-5.26% on volume of 4,899 shares), positioning the stock +22.33% above its 50-day simple moving average ($1.03) and -16.56% below its 200-day simple moving average ($1.51). Across its 52-week range of $0.68 to $2.50, AHG sits at the 31.9% percentile with a 14-day RSI of 57.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.10 to $1.42).

AHG Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is AHG's 12-month stock price target?

Akso Health Group ADS (AHG) carries a 12-month consensus base price target of $1.12 (-11.1% from $1.26), with a bull-case target of $2.63 and a bear-case floor of $0.87.

Is AHG stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates AHG E (Strong Sell — SELL) with an RQD Confidence score of 34/100.

Direct Sub-Reports: AHG RQD Cockpit AHG 12M Forecast AHG Earnings & Move AHG Dividends & DRIP AHG Insiders & 13F AHG Whale Options AHG Profit Sankey AHG News & Why

ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

AHG — Akso Health Group ADS: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:30:34Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, AHG holds a score of 34 out of 100, a letter grade of E, and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the fundamental cash engine scores 8 out of 20, with ROIC at 0% and an FCF yield of -1.12%, indicating the business is not currently converting capital into returns or positive free cash flow. The whale 13F flow pillar scores 10 out of 20, reflecting institutional accumulation and options positioning that is weaker than the top of the scale. Insider conviction scores 3 out of 20, the lowest pillar, drawn from the SEC Form 4 and Congressional PTR cluster flow. Macro regime fit scores 5 out of 20 with a beta of 1.0 and sector sensitivity noted. Forensic balance sheet scores 8 out of 20, citing an Altman Z of 2.5, a Piotroski F of 2 out of 9, and a Debt/Equity of 0.5. For a prospective investor, the upside case rests on any reversal in cash generation, which the rating does not currently show, while the valuation tradeoff is that a low share price alone does not offset negative returns on capital. The cumulative pillar profile signals elevated forensic risk and weak insider conviction rather than a constructive setup.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$13.8M	$-20.7M	$-18.7M	N/A	$-12.8M	N/A	N/A
FY 2024	$14.8M	$-166.3M	$-135.0M	N/A	$1.0M	N/A	N/A
FY 2023	$2.4M	$-8.6M	$-9.5M	N/A	$1.4M	N/A	N/A

Per the SEC financials, operating margin is -60% and net margin is -60%, with gross margin at -0.1% in the market data. ROIC is 0%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2 out of 9, per the Roarable RQD rating. Debt/Equity is 0.5 per the same source. Cash and debt balances are not available in source data for any reported period.

Open Questions

What are the specific cash and debt balances behind the reported Debt/Equity of 0.5 and the FY periods?
What drove the FY 2024 operating loss of $-166.3M against revenue of $14.8M, and does the FY 2025 figure reflect a structural change?
What is the EPS for any period, given that EPS is listed as N/A across all three filings?
What supply-chain or sector links exist, given the butterfly graph reports no supply chain and no links?
What is the source and timing of the 0% dividend yield and the institutional flow behind the whale pillar score?

AHG Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Akso Health Group ADS (AHG) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AHG Debate Forum (3) ↓

🟢 CATALYST Yahoo • 17d ago

Akso Health Group (AHG) Stock May Look Pricey Against Its Book Value

Akso Health Group has seen sharp swings in recent years, and the latest moves raise a simple question for you as a shareholder or potential buyer. Is the current share price in line with what the company’s book value can

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 94d ago

Akso Health Group (AHG) Is Up 8.2% After Auditor Flags Going Concern Risk Despite Narrower Losses

In July 2026, Akso Health Group reported full-year results for the period ended March 31, 2026, showing sales of US$13.84 million and a net loss of US$18.67 million, alongside materially lower loss per share than a year

Read Full Source ↗

🟡 MARKET WIRE Targeting the Next Frontier of Human Neurotechnology • 189d ago

AHG Announces Initiation of World-Class, Proprietary Brain-Computer Interface R&D Program

Akso Health Group (NASDAQ: AHG) ("Akso Health" or the "Company") today announced the commencement of its next-generation, proprietary Brain-Computer Interface (BCI) technology research and development program. The Compan

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 272d ago

Akso Health Group Announces Launch of Exploratory Global Patient Support Initiative

Akso Health Group (NASDAQ: AHG) ("Akso Health" or the "Company") today announced the launch of the an exploratory patient support program and a strategic cooperation with Nanning Duoling Research Institute. Adopting an i

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 352d ago

While Akso Health Group (NASDAQ:AHG) shareholders have made 235% in 3 years, increasing losses might now be front of mind as stock sheds 10% this week

Yahoo Finance coverage on AHG stock catalysts, institutional flow, and earnings outlook.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 10d ago

Akso Health Group Estimates – NASDAQ:AHG

<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE9LTXc1MURydmdGcFBPc0xqZ3N2MFJLaXd0Zy1IS1VfdU4tMXV2RU50aDJwS3AwQkhLUTF6ZUdoUXFvbDhOQ0oxYVRyc3BrYXFyWnE3YjZkVU0zbG1EVXdrX2NudDdVN2VwYmQ0YkNOcmpNem04cnFB?oc=5"

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 11d ago

Akso Health Group (NASDAQ:AHG) Stock Price Up 6.8% - Here's What Happened

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxOSmF3UjZRbjRRWEdaZGhYcXIxbExRLXM1Ui05Zk9IcmpuSEdoQ19NSzhuWHJ5QTJ1bjMxY3hQbXloNFFteUFTb2ljVnItVUJPbFRzRlVmSjZGajlDa0FGeEUzNG4xS0VQbEZjekFORm9NOS1OT0FmSWFfMXV

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 8d ago

TOP Financial Group (TOP) Stock Looks Rich Following Its 203% Run

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNaE9ub2pGWnhKcE9QQjV0NjdnTGxpNUMyUm9aMllGS0NiLUNqcGZnYk5LbGFCUTNqRkdHQVJLM1FQLVZvZVNmcXUyMmdDWkd0bE9NM0FSNl84Y3EyU2pBZjZHekNDTVFYQUV4ZnIwZUcwckEwbFBVdU4tc2x

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AHG Bull vs. Bear Conversation Board — What's Your Call at $1.26?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AHG 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.17 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is AHG (E • RQD 34/100) a Buy at $1.33?

Welcome to the AHG (Akso Health Group ADS) Roar Pit. Current RQD Composite is 34/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Business Services. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.05 (-21.1%)

Spot @ $1.33

Pump the brakes on AHG — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on AHG, but look at what you are paying: current EV/EBITDA multiples with -0.1% gross margins. Unless Akso Health Group ADS expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.58 (+18.8%)

Spot @ $1.33

AHG cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on AHG, the market is fixating on short-term headline noise in Business Services and ignoring the balance sheet and cash flow trajectory. At $1.33 (52-wk range $0.68 - $2.50), any beat on forward guidance forces shorts and underweight funds to chase.